Associated Papers
mTOR Variants Activation Discovers PI3K-like Cryptic Pocket, Expanding Allosteric, Mutant-Selective Inhibitor Designs.
Liu Y et al.
Journal of Chemical Information and Modeling, 2025
39792006 (PubMed )
Supplement: ci4c02022_si_002.xlsx › Sheet1
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy.
Jóri B et al.
Cancers, 2021
34201252 (PubMed )
Supplement: cancers-13-02861-s001.zip › cancers-1214406-supplementary.pdf
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM et al.
International Journal of Cancer, 2020
Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.
Rodríguez-Moreno JF et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2017
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
Hortobagyi GN et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2016
Select a paper to view details